Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios


suck pdf from google scholar
unlimited free pdf from europmc32497535    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32497535  :  Publisher
PDF vom PMID32497535

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19 #MMPMID32497535
  • Dalamaga M; Karampela I; Mantzoros CS
  • Metabolism 2020[Aug]; 109 (ä): 154282 PMID32497535show ga
  • The most severe presentation of COVID-19 is characterized by a hyperinflammatory state attributed to the massive pro-inflammatory cytokine release, called "cytokine storm". Several specific anti-inflammatory/immunosuppressive agents are being evaluated by ongoing clinical trials; however, there is currently insufficient evidence for their efficacy and safety in COVID-19 treatment. Given the role of phosphodiesterase 4 (PDE) 4 and cyclic adenosine monophosphate in the inflammatory response, we hypothesize that selective PDE4 inhibition may attenuate the cytokine storm in COVID-19, through the upstream inhibition of pro-inflammatory molecules, particularly TNF-alpha, and the regulation of the pro-inflammatory/anti-inflammatory balance. Conversely, other anti-cytokine agents lead to the downstream inhibition of specific targets, such as IL-1, IL-6 or TNF-alpha, and may not be efficient in blocking the cytokine storm, once it has been triggered. Due to their mechanism of action targeting an early stage of the inflammatory response and ameliorating lung inflammation, we believe that selective PDE4 inhibitors may represent a promising treatment option for the early phase of COVID-19 pneumonia before the cytokine storm and severe multiorgan dysfunction take place. Furthermore, PDE4 inhibitors present several advantages including an excellent safety profile; the oral route of administration; the convenient dosing; and beneficial metabolic properties. Interestingly, obesity and diabetes mellitus type 2 have been reported to be risk factors for the severity of COVID-19. Therefore, randomized clinical trials of PDE4 inhibitors are necessary to explore their potential therapeutic effect as an adjunct to supportive measures and other therapeutic regiments.
  • |*Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy/etiology/immunology[MESH]
  • |Cyclic AMP/metabolism[MESH]
  • |Cytokine Release Syndrome/*drug therapy[MESH]
  • |Humans[MESH]
  • |Interleukin-17/antagonists & inhibitors[MESH]
  • |Obesity/complications[MESH]
  • |Pandemics[MESH]
  • |Phosphodiesterase 4 Inhibitors/*therapeutic use[MESH]
  • |Pneumonia, Viral/*drug therapy/etiology/immunology[MESH]
  • |SARS-CoV-2[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    154282 ä.109 2020